Close

Amarin Corp. (AMRN) Misses Q3 EPS by 2c, Revenues Beat

Go back to Amarin Corp. (AMRN) Misses Q3 EPS by 2c, Revenues Beat

Amarin (AMRN) Q4 'Very Strong', Seen as 'Great Tuck-In' for Big Pharma - Jefferies

February 27, 2019 12:52 PM EST

Jefferies analyst Michael Yee weighed in on Amarin Corporation (NASDAQ: AMRN) following "very strong" Q4 results as the company is working hard to file the sNDA to expand the label by 10x to a broad CV population this quarter.

Yee notes... More